Why Lakefront Biotherapeutics NV’s (LKFT) Stock Is Up 6.27%
As of Wednesday, August 19, Lakefront Biotherapeutics NV’s LKFT share price has surged by 6.27%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Commentary & Analysis
Why Lakefront Biotherapeutics NV’s (LKFT) Stock Is Up 6.22%
As of Wednesday, August 19, Lakefront Biotherapeutics NV’s LKFT share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Lakefront Biotherapeutics NV’s (LKFT) Stock Is Up 5.86%
As of Wednesday, August 19, Lakefront Biotherapeutics NV’s LKFT share price has surged by 5.86%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is Lakefront Biotherapeutics NV (LKFT) Overvalued?
We dive into why Lakefront Biotherapeutics NV (LKFT) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Michael Rose
Does Lakefront Biotherapeutics NV (LKFT) Have Momentum?
With data as of May 11, 2026, we examine if Lakefront Biotherapeutics NV(LKFT) is consistently building momentum based on AAII's A+ Investor Momentum and Value Scores and Grades.Michael Rose
Financial Summary
| Share Statistics | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,869.1 | $286.3 | 52% |
|
| Shares Out (Mil) | 75.4 | 54.2 | 56% |
|
| Institutional Ownership | 100.0% | 92.8% | 99% |
|
| Float (Mil) | 24.4 | 39.7 | 32% |
|
| Beta | 0.11 | 0.94 | 9% |
|
| Avg Daily Volume (000s) | 311 | 534 | 50% |
|
| Price Change (52-week) |
(12.0%) | 58.7% | 35% |
|
| Growth | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.4% | 13.6% | 77% |
|
| Net Income (5yr) | 24.6% | (10.1%) | 80% |
|
| EPS (5yr) | 24.5% | 16.0% | 75 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (39.2%) | (15.6%) | 12% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 3 | |
| Current EPS | ($0.450) | ($0.829) | ($1.394) | |
| Month Ago EPS | ($0.572) | ($15.464) | ($2.003) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.530) | ($2.680) | ($2.719) | |
| Year/Year Chg | (1,424%) | (114.6%) | (135.5%) | |
| Financials | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,132 | $37 | 52% |
|
| Net Income (TTM) (Mil) | $682 | ($43) | 82% |
|
| EPS (TTM) | $10.345 | ($1.400) | 94% |
|
| Operating Cash Flow (TTM) (Mil) | ($259) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $40 | $2 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | ($639) | $160 | 0% |
|
| Valuation | LKFT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.50 | 2.77 | 8% |
|
| P/E | 2.7 | 19.1 | 2% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 1.0 | 3% |
|
| Ratios | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 67.6% | 64.2% | 79% |
|
| Net Margin | 60.2% | (75.9%) | 98% |
|
| ROA | 16.7% | (47.3%) | 94% |
|
| ROE | 20.4% | (55.0%) | 80% |
|
| Liabilities to Assets | 2.6% | 29.6% | 1% |
|
| F-Score | 3 | 2 | na |
|
Lakefront Biotherapeutics NV did not pass any screens on 8/20/2026.
